<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21081778</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>01</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>02</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1526-7598</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>112</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anesthesia and analgesia</Title>
                <ISOAbbreviation>Anesth. Analg.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>454-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1213/ANE.0b013e3182025b15</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the present study we examined the effect of the tumor necrosis factor (TNF)-α antagonist etanercept on the antinociceptive effect of morphine in morphine-tolerant rats.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Male Wistar rats were implanted with 2 intrathecal catheters, and 1 was connected to a mini-osmotic pump for either morphine (15 μg/h) or saline (1 μL/h) infusion for 5 days. On day 5, either etanercept (5 μg, 25 μg, and 50 μg/10 μL) or saline (10 μL) was injected via the other catheter after morphine infusion was discontinued. Three hours later, morphine (15 μg/10 μL, intrathecally) was given and tail-flick latency was measured to evaluate the antinociceptive effect of morphine. Rats were then killed and their spinal cords were removed for quantitative real-time polymerase chain reaction and immunohistochemistry to measure proinflammatory cytokines expression.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that acute etanercept (50 μg) treatment preserved a significant antinociceptive effect of morphine in morphine-tolerant rats. In addition, the expression of TNFα mRNA was increased by 2.5-fold, interleukin (IL)-1β mRNA increased by 13-fold and IL-6 mRNA by 111-fold in the dorsal spinal cord of morphine-tolerant rats. The increase in TNFα, IL-1β, and IL-6 mRNA expression was blocked by 50 μg etanercept pretreatment. The immunohistochemistry analysis revealed that 50 μg etanercept suppressed proinflammatory cytokines expression and neuroinflammation in the microglia.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present study demonstrates that etanercept restores the antinociceptive effect of morphine in morphine-tolerant rats by inhibition of proinflammatory cytokine TNF-α, IL-1β, and IL-6 expression and spinal neuroinflammation. The results suggest that etanercept could also be an adjuvant therapy for morphine tolerance, which extends the effectiveness of opioids in clinical pain management.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Ching-Hui</ForeName>
                    <Initials>CH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsai</LastName>
                    <ForeName>Ru-Yin</ForeName>
                    <Initials>RY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shih</LastName>
                    <ForeName>Meng-Shen</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Shinn-Long</ForeName>
                    <Initials>SL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tai</LastName>
                    <ForeName>Yueh-Hwa</ForeName>
                    <Initials>YH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chien</LastName>
                    <ForeName>Chih-Cheng</ForeName>
                    <Initials>CC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>Chih-Shung</ForeName>
                    <Initials>CS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Anesth Analg</MedlineTA>
            <NlmUniqueID>1310650</NlmUniqueID>
            <ISSNLinking>0003-2999</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>185243-69-0</RegistryNumber>
                <NameOfSubstance UI="C106167">TNFR-Fc fusion protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>76I7G6D29C</RegistryNumber>
                <NameOfSubstance UI="D009020">Morphine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000701">Analgesics, Opioid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001522">Behavior, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004361">Drug Tolerance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007074">Immunoglobulin G</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018836">Inflammation Mediators</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007260">Infusion Pumps</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007263">Infusions, Parenteral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007278">Injections, Spinal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053583">Interleukin-1beta</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017628">Microglia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009020">Morphine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017288">Pain Threshold</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011930">Reaction Time</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018124">Receptors, Tumor Necrosis Factor</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013116">Spinal Cord</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ANE.0b013e3182025b15</ArticleId>
            <ArticleId IdType="doi">10.1213/ANE.0b013e3182025b15</ArticleId>
            <ArticleId IdType="pubmed">21081778</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12602712</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>02</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>03</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0038-4348</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>96</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Southern medical journal</Title>
                <ISOAbbreviation>South. Med. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Reye's syndrome: down but not out.</ArticleTitle>
            <Pagination>
                <MedlinePgn>43-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Reye's syndrome presents as acute central nervous system and liver dysfunction in children. Its incidence has seen a sharp decline in parallel with the decline in the use of aspirin in the pediatric age group. This report describes a patient with Reye's syndrome and serves as a reminder for health professionals to continue to discourage the use of aspirin for the treatment of viral infections.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bhutta</LastName>
                    <ForeName>Adnan T</ForeName>
                    <Initials>AT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR 72202-3591, USA. bhuttaadnant@uams.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Savell</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schexnayder</LastName>
                    <ForeName>Stephen M</ForeName>
                    <Initials>SM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>South Med J</MedlineTA>
            <NlmUniqueID>0404522</NlmUniqueID>
            <ISSNLinking>0038-4348</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R16CO5Y76E</RegistryNumber>
                <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001241">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005334">Fever</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012141">Respiratory Tract Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012202">Reye Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>27</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>27</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12602712</ArticleId>
            <ArticleId IdType="doi">10.1097/01.SMJ.0000047764.97329.1C</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1658990</PMID>
        <DateCreated>
            <Year>1991</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1991</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0035-9203</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>85</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <MedlineDate>1991 May-Jun</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Transactions of the Royal Society of Tropical Medicine and Hygiene</Title>
                <ISOAbbreviation>Trans. R. Soc. Trop. Med. Hyg.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Kala-azar in displaced people from southern Sudan: epidemiological, clinical and therapeutic findings.</ArticleTitle>
            <Pagination>
                <MedlinePgn>365-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Six hundred and ninety-three patients with kala-azar were seen in Khartoum, Sudan, from January 1989 to February 1990. They were almost exclusively from the Nuer tribe, originating from the western Upper Nile province in southern Sudan, an area not known previously to be endemic for kala-azar. Because of the civil war in southern Sudan no treatment was available locally and massive migration to northern Sudan occurred; many died on the way. All age groups were affected; there was a slight male preponderance (56%). In the clinical presentation, marked generalized lymphadenopathy was prominent (84%). Splenomegaly was absent in 4% of cases. Patients usually showed anaemia, leucopenia and/or thrombocytopenia. 623 patients were treated with sodium stibogluconate, 10 mg/kg for 30 d; relapse occurred in 4% and death in 12%. Latterly, 70 patients were treated with sodium stibogluconate at 2 x 10 mg/kg for 15 d, with relapse in 6% and death in 6%. The difference between the 2 regimens in the number of relapses and deaths was not significant. The outbreak may have been caused by a combination of factors: the introduction of the parasite from an endemic area to a non-immune population, the presence of malnutrition caused by loss of cattle and unavailability of other food sources, and possibly an ecological change in favour of the sandfly vector.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zijlstra</LastName>
                    <ForeName>E E</ForeName>
                    <Initials>EE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Leishmaniasis Research Group, Medical Research Council, Sudan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ali</LastName>
                    <ForeName>M S</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>el-Hassan</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>el-Toum</LastName>
                    <ForeName>I A</ForeName>
                    <Initials>IA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Satti</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghalib</LastName>
                    <ForeName>H W</ForeName>
                    <Initials>HW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sondorp</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Winkler</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Trans R Soc Trop Med Hyg</MedlineTA>
            <NlmUniqueID>7506129</NlmUniqueID>
            <ISSNLinking>0035-9203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>V083S0159D</RegistryNumber>
                <NameOfSubstance UI="D000967">Antimony Sodium Gluconate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000967">Antimony Sodium Gluconate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001772">Blood Cell Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004196">Disease Outbreaks</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007898">Leishmaniasis, Visceral</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008206">Lymphatic Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013163">Splenomegaly</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D013397">Sudan</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014171">Transients and Migrants</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1991</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1991</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1991</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1658990</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19317712</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1365-2044</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>64</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anaesthesia</Title>
                <ISOAbbreviation>Anaesthesia</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Post induction arrhythmia in a renal patient: an unexpected risk factor.</ArticleTitle>
            <Pagination>
                <MedlinePgn>439-43</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2044.2008.05783.x</ELocationID>
            <Abstract>
                <AbstractText>A 44 year-old woman was anaesthetised for a transplant nephrectomy. About 10 min after induction of anaesthesia she had several runs of ventricular tachycardia followed by ventricular fibrillation requiring 30 s of cardiopulmonary resuscitation, after which she reverted to sinus rhythm. Review of her chest X-ray, suggested that the haemodialysis catheter (Permcath) position may have precipitated this event. However, subsequent investigation found that she had toxic serum levels of sotalol, with a prolonged corrected QT interval on the electrocardiogram. She was started on sotalol while her renal graft was functioning well but it was not reviewed when the graft started to fail and she had to commence haemodialysis. This led to the accumulation of sotalol and explains her serum sotalol value of 7.1 mg x l(-1) on the day of the event. Concentrations greater than 2.5 mg x l(-1) are generally considered toxic.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Srivastava</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Guy's &amp; St Thomas Hospital, London, UK. amit4@doctors.org.uk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khan</LastName>
                    <ForeName>M Ahmed</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watkiss</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Anaesthesia</MedlineTA>
            <NlmUniqueID>0370524</NlmUniqueID>
            <ISSNLinking>0003-2409</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A6D97U294I</RegistryNumber>
                <NameOfSubstance UI="D013015">Sotalol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000319">Adrenergic beta-Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000889">Anti-Arrhythmia Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007431">Intraoperative Complications</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016030">Kidney Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009392">Nephrectomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006435">Renal Dialysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013015">Sotalol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017180">Tachycardia, Ventricular</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014693">Ventricular Fibrillation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ANA5783</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2044.2008.05783.x</ArticleId>
            <ArticleId IdType="pubmed">19317712</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6946118</PMID>
        <DateCreated>
            <Year>1982</Year>
            <Month>01</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1982</Year>
            <Month>01</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-8177</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>102</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1981</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the American Dental Association (1939)</Title>
                <ISOAbbreviation>J Am Dent Assoc</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Diazepam-induced thrombophlebitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>824, 826</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dionne</LastName>
                    <ForeName>R A</ForeName>
                    <Initials>RA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Am Dent Assoc</MedlineTA>
            <NlmUniqueID>7503060</NlmUniqueID>
            <ISSNLinking>0002-8177</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>Q3JTX2Q7TU</RegistryNumber>
                <NameOfSubstance UI="D003975">Diazepam</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>D</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000766">Anesthesia, Dental</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003975">Diazepam</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013924">Thrombophlebitis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1981</Year>
                <Month>6</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1981</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1981</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6946118</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20473075</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>05</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>01</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1533-712X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>30</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical psychopharmacology</Title>
                <ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clozapine-associated cerebral venous thrombosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>335-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0b013e3181deb88a</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Srinivasaraju</LastName>
                    <ForeName>Ravindra</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reddy</LastName>
                    <ForeName>Y C Janardhan</ForeName>
                    <Initials>YC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pal</LastName>
                    <ForeName>Pramod K</ForeName>
                    <Initials>PK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Math</LastName>
                    <ForeName>Suresh Bada</ForeName>
                    <Initials>SB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Clin Psychopharmacol</MedlineTA>
            <NlmUniqueID>8109496</NlmUniqueID>
            <ISSNLinking>0271-0749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>J60AR2IKIC</RegistryNumber>
                <NameOfSubstance UI="D003024">Clozapine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003024">Clozapine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003392">Cranial Sinuses</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020767">Intracranial Thrombosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0b013e3181deb88a</ArticleId>
            <ArticleId IdType="pii">00004714-201006000-00022</ArticleId>
            <ArticleId IdType="pubmed">20473075</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18172224</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>01</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1074-2484</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cardiovascular pharmacology and therapeutics</Title>
                <ISOAbbreviation>J. Cardiovasc. Pharmacol. Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature.</ArticleTitle>
            <Pagination>
                <MedlinePgn>298-303</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1074248407306671</ELocationID>
            <Abstract>
                <AbstractText>The purpose of this article was to determine the incidence of in-stent thrombosis (IST) after coronary stent implantation in patients with cocaine abuse. A retrospective review was done of medical records of consecutive patients who underwent coronary stent implantation for obstructive coronary artery disease at a single inner-city institution from January 1997 to October 2006. Patients with temporal cocaine use were identified by positive urine drug screen. IST was confirmed angiographically. Of the 81 patients with active cocaine use that underwent coronary stent implantation, 4 (5%) suffered IST (mean period from stent implantation, 28.5 +/- 14 days). All procedures were performed successfully and received intravenous IIb/IIIa antagonist intraprocedurally. All patients were prescribed dual antiplatelet therapy with aspirin and clopidogrel at discharge; however, all 4 patients that suffered from IST continued cocaine abuse were noncompliant with the prescribed dual antiplatelet therapy. Of these 4 patients, 2 presented with ST segment elevation myocardial infarction (50%), whereas 2 presented with non-ST-segment elevation myocardial infarction (50%). One was managed medically. Two received repeat percutaneous coronary intervention, and 1 underwent coronary artery bypass surgery. The patient that underwent surgery died in the postoperative period. The remaining 3 patients survived. Patients with active cocaine abuse who undergo successful coronary stent revascularization have a high (5%) incidence of stent thrombosis. A majority of patients that suffer stent thrombosis continue cocaine abuse and are noncompliant with antiplatelet therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Sarabjeet</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Chicago Medical School, Illinois.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arora</LastName>
                    <ForeName>Rohit</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khraisat</LastName>
                    <ForeName>Ahmad</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Handa</LastName>
                    <ForeName>Kamna</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bahekar</LastName>
                    <ForeName>Amol</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trivedi</LastName>
                    <ForeName>Atul</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khosla</LastName>
                    <ForeName>Sandeep</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Cardiovasc Pharmacol Ther</MedlineTA>
            <NlmUniqueID>9602617</NlmUniqueID>
            <ISSNLinking>1074-2484</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A74586SNO7</RegistryNumber>
                <NameOfSubstance UI="C055162">clopidogrel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>OM90ZUW7M1</RegistryNumber>
                <NameOfSubstance UI="D013988">Ticlopidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R16CO5Y76E</RegistryNumber>
                <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015906">Angioplasty, Balloon, Coronary</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001241">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003324">Coronary Artery Disease</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003328">Coronary Thrombosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010975">Platelet Aggregation Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D015607">Stents</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013988">Ticlopidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>24</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">12/4/298</ArticleId>
            <ArticleId IdType="doi">10.1177/1074248407306671</ArticleId>
            <ArticleId IdType="pubmed">18172224</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8156857</PMID>
        <DateCreated>
            <Year>1994</Year>
            <Month>05</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1994</Year>
            <Month>05</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0012-4486</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>84</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1993</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Documenta ophthalmologica. Advances in ophthalmology</Title>
                <ISOAbbreviation>Doc Ophthalmol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Terson's syndrome in a patient with acute promyelocytic leukemia on all-trans retinoic acid treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>373-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The syndrome of vitreous hemorrhage in association with any form of intracranial bleeding is known as Terson's syndrome. Acute promyelocytic leukemia (APL) constitutes 5% to 15% of cases of acute nonlymphocytic leukemias, in which hemorrhagic diathesis often occurs and results in a rapid fatal outcome. In this report we describe a patient with APL who developed cerebral bleeding in association with bilateral subhyaloid and vitreous hemorrhages consistent with Terson's syndrome while she was on all-trans retinoic acid induction therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Abu el-Asrar</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>al-Momen</LastName>
                    <ForeName>A K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harakati</LastName>
                    <ForeName>M S</ForeName>
                    <Initials>MS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>NETHERLANDS</Country>
            <MedlineTA>Doc Ophthalmol</MedlineTA>
            <NlmUniqueID>0370667</NlmUniqueID>
            <ISSNLinking>0012-4486</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>5688UTC01R</RegistryNumber>
                <NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002543">Cerebral Hemorrhage</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005654">Fundus Oculi</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015473">Leukemia, Promyelocytic, Acute</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014057">Tomography, X-Ray Computed</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014212">Tretinoin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014823">Vitreous Hemorrhage</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1993</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1993</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1993</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8156857</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8215636</PMID>
        <DateCreated>
            <Year>1993</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1993</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-4932</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>218</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1993</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of surgery</Title>
                <ISOAbbreviation>Ann. Surg.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neutrophil and nonneutrophil-mediated injury in intestinal ischemia-reperfusion.</ArticleTitle>
            <Pagination>
                <MedlinePgn>444-53; discussion 453-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The role of polymorphonuclear neutrophils (PMN) was examined in local and remote organ injury after intestinal ischemia-reperfusion.</AbstractText>
                <AbstractText Label="SUMMARY BACKGROUND DATA" NlmCategory="BACKGROUND">PMN have been found to mediate the local injury in low flow intestinal ischemia-reperfusion. However, in complete intestinal ischemia-reperfusion, prevention of PMN adhesion by monoclonal antibodies to CD11b and CD18 reduces remote but not local intestinal injury. The role of PMN was further investigated in this setting.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In a rat model of 1-hour complete intestinal ischemia and 4-hour reperfusion. PMN were manipulated in the following four ways: (1) inhibition of oxygen-free radicals using manganese superoxide dismutase and catalase (SOD/CAT), (2) antagonism of PMN elastase using secretory leukocyte protease inhibitor (SLPI), (3) neutropenia using PMN antisera, and (4) inhibition of activation and adhesion using interleukin-1 receptor antagonist (IL-1ra) and tumor necrosis factor binding protein (TNFbp). Lung injury was quantified by the pulmonary permeability index, which is the ratio of bronchoalveolar lavage to blood concentration of radiolabeled bovine serum albumin, and PMN sequestration by myeloperoxidase (MPO) activity. Liver injury was estimated by PMN counts using quantitative histologic examination and by serum glutamic pyruvic transaminase (SGPT). Local injury was quantified by MPO activity and histologic grading.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Neutropenia reduced the pulmonary permeability 80% from 11.0 +/- 0.5 x 10(-3) with saline treatment to 5.50 +/- 0.12 x 10(-3); IL-1ra, to 5.62 +/- 0.44 x 10(-3); and TNFbp, to 4.32 +/- 0.18 x 10(-3) (all p &lt; 0.05). Pulmonary MPO rose from 0.03 +/- 0.01 U/g to 0.25 +/- 0.03 U/g (p &lt; 0.05). This was reduced by neutropenia, 0.01 +/- 0.003 U/g, but not by inhibition of oxygen-free radicals or PMN elastase. IL-1ra inhibited PMN sequestration, reducing MPO to 0.12 +/- 0.01 (p &lt; 0.05). Liver injury was 60% dependent on PMN. Ischemia-reperfusion increased SGPT from 20.3 +/- 0.7 IU/L in the sham-treated animals to 97.0 +/- 3.1 IU/L in the experimental animals. Neutropenia reduced this to 48.1 +/- 3.9 IU/L; IL-1ra, to 44.7 +/- 3.7 IU/L; SOD/CAT, to 64.0 +/- 3.38 IU/L; and SLPI, to 57.1 +/- 3.4 IU/L (p &lt; 0.05 in all cases). Local injury was severe and unaffected by manipulation of the PMN.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data suggest that PMN and their products mediate most of the lung, part of the liver, and none of the local gut injury after intestinal ischemia-reperfusion.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Simpson</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alon</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kobzik</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valeri</LastName>
                    <ForeName>C R</ForeName>
                    <Initials>CR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shepro</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hechtman</LastName>
                    <ForeName>H B</ForeName>
                    <Initials>HB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>GM24891-14</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>GM35141-06</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL43875-02</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Ann Surg</MedlineTA>
            <NlmUniqueID>0372354</NlmUniqueID>
            <ISSNLinking>0003-4932</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.7</RegistryNumber>
                <NameOfSubstance UI="D009195">Peroxidase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Surgery. 1992 Aug;112(2):166-72</RefSource>
                <PMID Version="1">1353637</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Appl Physiol (1985). 1992 Jul;73(1):317-23</RefSource>
                <PMID Version="1">1354669</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1992 Sep 1;149(5):1723-8</RefSource>
                <PMID Version="1">1387151</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1965 Aug;26:215-9</RefSource>
                <PMID Version="1">14332483</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Surg. 1970 Oct;101(4):478-83</RefSource>
                <PMID Version="1">5457245</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Res. 1979 Aug;45(2):292-7</RefSource>
                <PMID Version="1">376174</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1981 Jan 22;304(4):192-6</RefSource>
                <PMID Version="1">6969364</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1981 Dec;68(6):1394-403</RefSource>
                <PMID Version="1">7033282</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1982 May;242(5):G448-54</RefSource>
                <PMID Version="1">6896267</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Trauma. 1983 Apr;23(4):269-77</RefSource>
                <PMID Version="1">6842628</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1985 Feb;82(4):1204-8</RefSource>
                <PMID Version="1">3919388</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1985 Dec;135(6):3972-7</RefSource>
                <PMID Version="1">2999236</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1986 Apr;77(4):1233-43</RefSource>
                <PMID Version="1">3485659</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1986 Apr 17-23;320(6063):584-8</RefSource>
                <PMID Version="1">3010124</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1986 Sep;83(18):6692-6</RefSource>
                <PMID Version="1">3462719</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Physiol Scand Suppl. 1986;548:47-63</RefSource>
                <PMID Version="1">3529822</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Appl Physiol (1985). 1986 Dec;61(6):2224-9</RefSource>
                <PMID Version="1">3643211</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Surg. 1987 Apr;74(4):279-81</RefSource>
                <PMID Version="1">3580801</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lab Invest. 1987 Jun;56(6):583-90</RefSource>
                <PMID Version="1">3599906</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Methods. 1987 Sep;18(2):137-42</RefSource>
                <PMID Version="1">3041120</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pathol Immunopathol Res. 1987;6(3):153-76</RefSource>
                <PMID Version="1">3321021</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1988 Apr;81(4):1162-72</RefSource>
                <PMID Version="1">3258319</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Surg. 1988 Jul;208(1):71-7</RefSource>
                <PMID Version="1">3389946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Surg. 1988 Dec;208(6):761-7</RefSource>
                <PMID Version="1">3196099</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Rev Respir Dis. 1988 Nov;138(5):1300-7</RefSource>
                <PMID Version="1">3059892</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bacteriol. 1989 Apr;171(4):2166-72</RefSource>
                <PMID Version="1">2467900</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1989 May 15;264(14):7768-71</RefSource>
                <PMID Version="1">2470733</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1989 Jul 15;264(20):11974-80</RefSource>
                <PMID Version="1">2545693</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 1989 Sep;97(3):605-9</RefSource>
                <PMID Version="1">2502465</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Surgery. 1989 Aug;106(2):195-201; discussion 201-2</RefSource>
                <PMID Version="1">2763027</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1989 Aug;257(2 Pt 1):G299-307</RefSource>
                <PMID Version="1">2504053</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1989 Oct;257(4 Pt 2):R872-7</RefSource>
                <PMID Version="1">2802004</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1990 Jan 25;343(6256):336-40</RefSource>
                <PMID Version="1">2137200</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Surgery. 1990 Apr;107(4):372-80</RefSource>
                <PMID Version="1">2321134</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1990 Jun;85(6):1936-43</RefSource>
                <PMID Version="1">2161433</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1990 Jul 13;249(4965):146-51</RefSource>
                <PMID Version="1">2371562</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 1990 Nov;99(5):1358-63</RefSource>
                <PMID Version="1">2170222</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1990 Dec 6;348(6301):550-2</RefSource>
                <PMID Version="1">2147233</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Surg. 1990 Dec;212(6):694-700</RefSource>
                <PMID Version="1">2175168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1991 Apr 15;77(8):1627-52</RefSource>
                <PMID Version="1">1826616</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Free Radic Res Commun. 1991;12-13 Pt 2:725-35</RefSource>
                <PMID Version="1">2060844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Surg. 1991 Jun;78(6):651-5</RefSource>
                <PMID Version="1">2070226</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Appl Physiol (1985). 1991 Jun;70(6):2645-9</RefSource>
                <PMID Version="1">1885460</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1991 Sep;261(3 Pt 1):G490-6</RefSource>
                <PMID Version="1">1887895</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1991 Dec;88(6):2026-31</RefSource>
                <PMID Version="1">1752960</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Klin Wochenschr. 1991 Dec 15;69(21-23):1056-60</RefSource>
                <PMID Version="1">1798279</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Rev Respir Dis. 1992 Jun;145(6):1410-5</RefSource>
                <PMID Version="1">1596010</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1990 Aug;259(2 Pt 1):G300-5</RefSource>
                <PMID Version="1">2166441</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1990 Sep;87(17):6758-61</RefSource>
                <PMID Version="1">1697688</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007410">Intestinal Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007413">Intestinal Mucosa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008168">Lung</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009504">Neutrophils</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009195">Peroxidase</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015427">Reperfusion Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014841">von Willebrand Factor</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1242997</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1993</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1993</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1993</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8215636</ArticleId>
            <ArticleId IdType="pmc">PMC1242997</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24836286</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>03</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk.</ArticleTitle>
            <Pagination>
                <MedlinePgn>533-42</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2985</ELocationID>
            <Abstract>
                <AbstractText>Known genetic loci explain only a small proportion of the familial relative risk of colorectal cancer (CRC). We conducted a genome-wide association study of CRC in East Asians with 14,963 cases and 31,945 controls and identified 6 new loci associated with CRC risk (P = 3.42 × 10(-8) to 9.22 × 10(-21)) at 10q22.3, 10q25.2, 11q12.2, 12p13.31, 17p13.3 and 19q13.2. Two of these loci map to genes (TCF7L2 and TGFB1) with established roles in colorectal tumorigenesis. Four other loci are located in or near genes involved in transcriptional regulation (ZMIZ1), genome maintenance (FEN1), fatty acid metabolism (FADS1 and FADS2), cancer cell motility and metastasis (CD9), and cell growth and differentiation (NXN). We also found suggestive evidence for three additional loci associated with CRC risk near genome-wide significance at 8q24.11, 10q21.1 and 10q24.2. Furthermore, we replicated 22 previously reported CRC-associated loci. Our study provides insights into the genetic basis of CRC and suggests the involvement of new biological pathways.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Ben</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Wei-Hua</ForeName>
                    <Initials>WH</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuda</LastName>
                    <ForeName>Koichi</ForeName>
                    <Initials>K</Initials>
                    <Identifier Source="ORCID">0000000172922686</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kweon</LastName>
                    <ForeName>Sun-Seog</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, South Korea. [2] Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital, Hwasun, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuo</LastName>
                    <ForeName>Keitaro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiang</LastName>
                    <ForeName>Yong-Bing</ForeName>
                    <Initials>YB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Aesun</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Molecular Epidemiology Branch, National Cancer Center, Goyang-si, South Korea. [2] Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jee</LastName>
                    <ForeName>Sun Ha</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Dong-Hyun</ForeName>
                    <Initials>DH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Social and Preventive Medicine, Hallym University College of Medicine, Okcheon-dong, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cai</LastName>
                    <ForeName>Qiuyin</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Long</LastName>
                    <ForeName>Jirong</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Jiajun</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">0000000151940009</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wen</LastName>
                    <ForeName>Wanqing</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Gong</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yanfeng</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Chun</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Bingshan</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ren</LastName>
                    <ForeName>Zefang</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Public Health, Sun Yat-sen University, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ji</LastName>
                    <ForeName>Bu-Tian</ForeName>
                    <Initials>BT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Epidemiology &amp; Genetics, National Cancer Institute, Bethesda, Maryland, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pan</LastName>
                    <ForeName>Zhi-Zhong</ForeName>
                    <Initials>ZZ</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Atsushi</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Integrative Medical Sciences, RIKEN, Kanagawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Min-Ho</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuda</LastName>
                    <ForeName>Fumihiko</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Yu-Tang</ForeName>
                    <Initials>YT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oh</LastName>
                    <ForeName>Jae Hwan</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Colorectal Cancer, National Cancer Center, Goyang-si, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Soriul</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Yoon-Ok</ForeName>
                    <Initials>YO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO)</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>Andrew T</ForeName>
                    <Initials>AT</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. [2] Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang-Claude</LastName>
                    <ForeName>Jenny</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Slattery</LastName>
                    <ForeName>Martha L</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Colorectal Transdisciplinary (CORECT) Study</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gruber</LastName>
                    <ForeName>Stephen B</ForeName>
                    <Initials>SB</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Southern California Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schumacher</LastName>
                    <ForeName>Fredrick R</ForeName>
                    <Initials>FR</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Southern California Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stenzel</LastName>
                    <ForeName>Stephanie L</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Southern California Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Colon Cancer Family Registry (CCFR)</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Casey</LastName>
                    <ForeName>Graham</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Southern California Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Hyeong-Rok</ForeName>
                    <Initials>HR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeong</LastName>
                    <ForeName>Jin-Young</ForeName>
                    <Initials>JY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Social and Preventive Medicine, Hallym University College of Medicine, Okcheon-dong, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Ji Won</ForeName>
                    <Initials>JW</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Center for Colorectal Cancer, National Cancer Center, Goyang-si, South Korea. [2] Department of Surgery, Seoul National University Hospital, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Hong-Lan</ForeName>
                    <Initials>HL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hosono</LastName>
                    <ForeName>Satoyo</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cho</LastName>
                    <ForeName>Sang-Hee</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hemato-oncology, Chonnam National University Medical School, Gwangju, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kubo</LastName>
                    <ForeName>Michiaki</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Integrative Medical Sciences, RIKEN, Kanagawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shu</LastName>
                    <ForeName>Xiao-Ou</ForeName>
                    <Initials>XO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeng</LastName>
                    <ForeName>Yi-Xin</ForeName>
                    <Initials>YX</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>HHSN268200764316C</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HHSN268201100001C</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HHSN268201100002C</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HHSN268201100003C</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HHSN268201100004C</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HHSN268201100046C</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HHSN271201100004C</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K05CA154337</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01CA055075</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01CA087969</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 DK058404</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30CA014089</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P50CA127003</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA059045</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA082729</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA122364</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA124558</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA148667</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01137178</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA042182</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA048998</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA059045</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA064277</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA076366</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA082729</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA092585</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA122364</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA124558</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA148667</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01CA81488</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R37 CA070867</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R37CA070867</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32ES013678</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32HG000040</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 CA074783</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 CA074794</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 CA074799</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 CA074800</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 CA097735</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 CA122839</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 CA137088</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01CA074783</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01CA074794</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01CA074799</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01CA074800</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01CA074806</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01CA097735</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01CA122839</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01CA137088</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01HG 004438</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01HG004446</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U24 CA074783</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U24 CA074794</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U24 CA074799</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U24 CA074800</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U24 CA097735</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UM1 CA173640</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UM1CA167552</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>Z01CP 010200</GrantID>
                    <Acronym>CP</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 1998 Jun;4(6):1507-10</RefSource>
                <PMID Version="1">9626469</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bone Miner Res. 1998 Oct;13(10):1569-76</RefSource>
                <PMID Version="1">9783545</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 1999 Jan;8(1):93-7</RefSource>
                <PMID Version="1">9887336</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2005 Jan 15;21(2):263-5</RefSource>
                <PMID Version="1">15297300</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2005 Dec 2;310(5753):1504-10</RefSource>
                <PMID Version="1">16293724</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Cell Biol. 2006 May;8(5):501-8</RefSource>
                <PMID Version="1">16604061</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2006 Jun 1;15(11):1745-56</RefSource>
                <PMID Version="1">16670158</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 Aug;38(8):904-9</RefSource>
                <PMID Version="1">16862161</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2006 Oct 1;66(19):9617-24</RefSource>
                <PMID Version="1">17018619</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 2014 Aug 15;135(4):948-55</RefSource>
                <PMID Version="1">24448986</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2006 Nov 1;24(31):5010-6</RefSource>
                <PMID Version="1">17075120</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2007 Jan 1;13(1):356-61</RefSource>
                <PMID Version="1">17200375</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2007 Jul;13(7):812-9</RefSource>
                <PMID Version="1">17589521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antioxid Redox Signal. 2007 Aug;9(8):1035-57</RefSource>
                <PMID Version="1">17567240</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2007 Aug;39(8):989-94</RefSource>
                <PMID Version="1">17618283</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2007 Aug;39(8):984-8</RefSource>
                <PMID Version="1">17618284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2007 Sep;81(3):559-75</RefSource>
                <PMID Version="1">17701901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 2007 Nov 15;121(10):2140-52</RefSource>
                <PMID Version="1">17582603</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2007 Oct 18;449(7164):851-61</RefSource>
                <PMID Version="1">17943122</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2007 Nov;39(11):1315-7</RefSource>
                <PMID Version="1">17934461</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2008 Jan;40(1):26-8</RefSource>
                <PMID Version="1">18084292</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2008 May;40(5):631-7</RefSource>
                <PMID Version="1">18372901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2008 May;40(5):623-30</RefSource>
                <PMID Version="1">18372905</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9697-702</RefSource>
                <PMID Version="1">18621708</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2008 Sep 5;321(5894):1361-5</RefSource>
                <PMID Version="1">18703712</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2008 Dec;40(12):1426-35</RefSource>
                <PMID Version="1">19011631</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2008 Dec 15;24(24):2938-9</RefSource>
                <PMID Version="1">18974171</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Mar;41(3):324-8</RefSource>
                <PMID Version="1">19219042</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Protoc. 2009;4(7):1073-81</RefSource>
                <PMID Version="1">19561590</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2009 Jul;37(Web Server issue):W600-5</RefSource>
                <PMID Version="1">19417063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Sep;41(9):986-90</RefSource>
                <PMID Version="1">19648918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2009 Dec 17;361(25):2449-60</RefSource>
                <PMID Version="1">20018966</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2010 Apr;7(4):248-9</RefSource>
                <PMID Version="1">20354512</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Jun;42(6):504-7</RefSource>
                <PMID Version="1">20453838</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2010 Jul;59(7):907-17</RefSource>
                <PMID Version="1">20581239</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Jul;42(7):599-603</RefSource>
                <PMID Version="1">20512145</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Sep 1;26(17):2190-1</RefSource>
                <PMID Version="1">20616382</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Sep;42(9):764-7</RefSource>
                <PMID Version="1">20729852</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Sep 15;26(18):2336-7</RefSource>
                <PMID Version="1">20634204</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2010 Sep 9;29(36):5006-18</RefSource>
                <PMID Version="1">20603617</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2010 Oct 8;87(4):545-52</RefSource>
                <PMID Version="1">20887962</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Nov;42(11):973-7</RefSource>
                <PMID Version="1">20972440</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genet Epidemiol. 2010 Dec;34(8):816-34</RefSource>
                <PMID Version="1">21058334</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50</RefSource>
                <PMID Version="1">20952405</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2011 Feb;39(3):781-94</RefSource>
                <PMID Version="1">20929870</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90</RefSource>
                <PMID Version="1">21296855</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4914-9</RefSource>
                <PMID Version="1">21383188</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2011;6(4):e19108</RefSource>
                <PMID Version="1">21526158</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):758-66</RefSource>
                <PMID Version="1">21357381</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2011 Jun;60(6):799-805</RefSource>
                <PMID Version="1">21242260</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2011 Jun;7(6):e1002105</RefSource>
                <PMID Version="1">21655089</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Oct;43(10):964-8</RefSource>
                <PMID Version="1">21892161</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Biotechnol. 2011 Nov;29(11):1019-23</RefSource>
                <PMID Version="1">22002653</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2012 Jan;40(Database issue):D930-4</RefSource>
                <PMID Version="1">22064851</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2012 Jan;40(Database issue):D1077-81</RefSource>
                <PMID Version="1">22064864</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2012 Jan;33(1):119-23</RefSource>
                <PMID Version="1">22072618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Feb 16;482(7385):390-4</RefSource>
                <PMID Version="1">22307276</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Jul;44(7):770-6</RefSource>
                <PMID Version="1">22634755</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Jul 19;487(7407):330-7</RefSource>
                <PMID Version="1">22810696</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Aug;44(8):955-9</RefSource>
                <PMID Version="1">22820512</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Sep 6;489(7414):57-74</RefSource>
                <PMID Version="1">22955616</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Oct;44(10):1084-9</RefSource>
                <PMID Version="1">22941192</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Nov 1;491(7422):56-65</RefSource>
                <PMID Version="1">23128226</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Feb;45(2):191-6</RefSource>
                <PMID Version="1">23263487</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Feb;45(2):136-44</RefSource>
                <PMID Version="1">23263490</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2013 Feb 21;494(7437):361-5</RefSource>
                <PMID Version="1">23376950</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2013 Apr;144(4):799-807.e24</RefSource>
                <PMID Version="1">23266556</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Apr;45(4):353-61, 361e1-2</RefSource>
                <PMID Version="1">23535729</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Apr;45(4):385-91, 391e1-2</RefSource>
                <PMID Version="1">23535732</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2013 Jun 15;22(12):2539-50</RefSource>
                <PMID Version="1">23535825</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Jun;45(6):580-5</RefSource>
                <PMID Version="1">23715323</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2013 Jul;133(7):1863-9</RefSource>
                <PMID Version="1">23426136</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Oct;45(10):1238-43</RefSource>
                <PMID Version="1">24013639</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2014 Feb;63(2):326-36</RefSource>
                <PMID Version="1">23946381</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3479-84</RefSource>
                <PMID Version="1">10725360</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2000 Jul 13;343(2):78-85</RefSource>
                <PMID Version="1">10891514</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Gastroenterol. 2001 Oct;96(10):2992-3003</RefSource>
                <PMID Version="1">11693338</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9924-9</RefSource>
                <PMID Version="1">12119409</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2003 May 15;63(10):2610-5</RefSource>
                <PMID Version="1">12750287</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2004 Apr;36(4):388-93</RefSource>
                <PMID Version="1">15052270</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2004 Oct;4(10):769-80</RefSource>
                <PMID Version="1">15510158</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1997 Nov 1;127(9):820-6</RefSource>
                <PMID Version="1">9382404</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1998 May 15;280(5366):1086-8</RefSource>
                <PMID Version="1">9582123</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044466">Asian Continental Ancestry Group</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002681">China</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002874">Chromosome Mapping</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000208">ethnology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019295">Computational Biology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D056426">Genetic Loci</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014644">Genetic Variation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D055106">Genome-Wide Association Study</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D056910">Republic of Korea</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012306">Risk</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS588441</OtherID>
        <OtherID Source="NLM">PMC4068797</OtherID>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Baron</LastName>
                <ForeName>John A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Berndt</LastName>
                <ForeName>Sonja I</ForeName>
                <Initials>SI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bezieau</LastName>
                <ForeName>Stéphane</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brenner</LastName>
                <ForeName>Hermann</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Caan</LastName>
                <ForeName>Bette J</ForeName>
                <Initials>BJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carlson</LastName>
                <ForeName>Christopher S</ForeName>
                <Initials>CS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Casey</LastName>
                <ForeName>Graham</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chan</LastName>
                <ForeName>Andrew T</ForeName>
                <Initials>AT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chang-Claude</LastName>
                <ForeName>Jenny</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chanock</LastName>
                <ForeName>Stephen J</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Conti</LastName>
                <ForeName>David V</ForeName>
                <Initials>DV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Curtis</LastName>
                <ForeName>Keith</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Duggan</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fuchs</LastName>
                <ForeName>Charles S</ForeName>
                <Initials>CS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gallinger</LastName>
                <ForeName>Steven</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Giovannucci</LastName>
                <ForeName>Edward L</ForeName>
                <Initials>EL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gruber</LastName>
                <ForeName>Stephen B</ForeName>
                <Initials>SB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Haile</LastName>
                <ForeName>Robert W</ForeName>
                <Initials>RW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Harrison</LastName>
                <ForeName>Tabitha A</ForeName>
                <Initials>TA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hayes</LastName>
                <ForeName>Richard B</ForeName>
                <Initials>RB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hoffmeister</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hopper</LastName>
                <ForeName>John L</ForeName>
                <Initials>JL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hsu</LastName>
                <ForeName>Li</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hudson</LastName>
                <ForeName>Thomas J</ForeName>
                <Initials>TJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hunter</LastName>
                <ForeName>David J</ForeName>
                <Initials>DJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hutter</LastName>
                <ForeName>Carolyn M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jackson</LastName>
                <ForeName>Rebecca D</ForeName>
                <Initials>RD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jenkins</LastName>
                <ForeName>Mark A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jiao</LastName>
                <ForeName>Shuo</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Küry</LastName>
                <ForeName>Sébastien</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Le Marchand</LastName>
                <ForeName>Loic</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lemire</LastName>
                <ForeName>Mathieu</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lindor</LastName>
                <ForeName>Noralane M</ForeName>
                <Initials>NM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ma</LastName>
                <ForeName>Jing</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Newcomb</LastName>
                <ForeName>Polly A</ForeName>
                <Initials>PA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peters</LastName>
                <ForeName>Ulrike</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Potter</LastName>
                <ForeName>John D</ForeName>
                <Initials>JD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Qu</LastName>
                <ForeName>Conghui</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rohan</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schoen</LastName>
                <ForeName>Robert E</ForeName>
                <Initials>RE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schumacher</LastName>
                <ForeName>Fredrick R</ForeName>
                <Initials>FR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seminara</LastName>
                <ForeName>Daniela</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Slattery</LastName>
                <ForeName>Martha L</ForeName>
                <Initials>ML</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thibodeau</LastName>
                <ForeName>Stephen N</ForeName>
                <Initials>SN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>White</LastName>
                <ForeName>Emily</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zanke</LastName>
                <ForeName>Brent W</ForeName>
                <Initials>BW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Blalock</LastName>
                <ForeName>Kendra</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Campbell</LastName>
                <ForeName>Peter T</ForeName>
                <Initials>PT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Casey</LastName>
                <ForeName>Graham</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Conti</LastName>
                <ForeName>David V</ForeName>
                <Initials>DV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Edlund</LastName>
                <ForeName>Christopher K</ForeName>
                <Initials>CK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Figueiredo</LastName>
                <ForeName>Jane</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gauderman</LastName>
                <ForeName>W James</ForeName>
                <Initials>WJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gong</LastName>
                <ForeName>Jian</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Green</LastName>
                <ForeName>Roger C</ForeName>
                <Initials>RC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gruber</LastName>
                <ForeName>Stephen B</ForeName>
                <Initials>SB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Harju</LastName>
                <ForeName>John F</ForeName>
                <Initials>JF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Harrison</LastName>
                <ForeName>Tabitha A</ForeName>
                <Initials>TA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jacobs</LastName>
                <ForeName>Eric J</ForeName>
                <Initials>EJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jenkins</LastName>
                <ForeName>Mark A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jiao</LastName>
                <ForeName>Shuo</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Li</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lin</LastName>
                <ForeName>Yi</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manion</LastName>
                <ForeName>Frank J</ForeName>
                <Initials>FJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moreno</LastName>
                <ForeName>Victor</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mukherjee</LastName>
                <ForeName>Bhramar</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peters</LastName>
                <ForeName>Ulrike</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Raskin</LastName>
                <ForeName>Leon</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schumacher</LastName>
                <ForeName>Fredrick R</ForeName>
                <Initials>FR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seminara</LastName>
                <ForeName>Daniela</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Severi</LastName>
                <ForeName>Gianluca</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stenzel</LastName>
                <ForeName>Stephanie L</ForeName>
                <Initials>SL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thomas</LastName>
                <ForeName>Duncan C</ForeName>
                <Initials>DC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Casey</LastName>
                <ForeName>Graham</ForeName>
                <Initials>G</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2985</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2985</ArticleId>
            <ArticleId IdType="pubmed">24836286</ArticleId>
            <ArticleId IdType="pmc">PMC4068797</ArticleId>
            <ArticleId IdType="mid">NIHMS588441</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18725507</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>10</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-009X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>36</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Drug metabolism and disposition: the biological fate of chemicals</Title>
                <ISOAbbreviation>Drug Metab. Dispos.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2277-86</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1124/dmd.108.023077</ELocationID>
            <Abstract>
                <AbstractText>Several cytochrome P450 (P450) enzymes have been identified in the heart, and their levels have been reported to be altered during cardiac hypertrophy. Moreover, there is a strong correlation between P450-mediated arachidonic acid metabolites and the pathogenesis of cardiac hypertrophy. Therefore, we investigated the effect of isoproterenol-induced cardiac hypertrophy on the expression of several P450 genes and their associated P450-derived metabolites of arachidonic acid. Cardiac hypertrophy was induced by seven daily i.p. injections of 5 mg/kg isoproterenol. Thereafter, the heart, lung, liver, and kidney were harvested, and the expression of different genes was determined by real-time polymerase chain reaction. Heart microsomal protein from control or isoproterenol treated rats was incubated with 50 microM arachidonic acid, and arachidonic acid metabolites were determined by liquid chromatography-electron spray ionization-mass spectrometry. Our results show that isoproterenol treatment significantly increased the heart/body weight ratio and the hypertrophic markers. In addition, there was a significant induction of CYP1A1, CYP1B1, CYP4A3, and soluble epoxide hydrolase and a significant inhibition of CYP2C11 and CYP2E1 in the hypertrophied hearts as compared with the control. CYP1A1, CYP2E1, and CYP4A3 gene expression was induced in the kidney, and CYP4A3 was induced in the liver of isoproterenol-treated rats. Isoproterenol treatment significantly reduced 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid formation and significantly increased their corresponding 8,9-, and 14,15-dihydroxyeicosatrienoic acid and the 20-hydroxyeicosatetraenoic acid metabolite. In conclusion, isoproterenol-induced cardiac hypertrophy alters arachidonic acid metabolism and its associated P450 enzymes, suggesting their role in the development and/or progression of cardiac hypertrophy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zordoky</LastName>
                    <ForeName>Beshay N M</ForeName>
                    <Initials>BN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, 3126 Dentistry/Pharmacy Centre, University of Alberta, Edmonton, AB, Canada T6G 2N8.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aboutabl</LastName>
                    <ForeName>Mona E</ForeName>
                    <Initials>ME</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>El-Kadi</LastName>
                    <ForeName>Ayman O S</ForeName>
                    <Initials>AO</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>08</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Drug Metab Dispos</MedlineTA>
            <NlmUniqueID>9421550</NlmUniqueID>
            <ISSNLinking>0090-9556</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>27YG812J1I</RegistryNumber>
                <NameOfSubstance UI="D016718">Arachidonic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9035-51-2</RegistryNumber>
                <NameOfSubstance UI="D003577">Cytochrome P-450 Enzyme System</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L628TT009W</RegistryNumber>
                <NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016718">Arachidonic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006332">Cardiomegaly</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003577">Cytochrome P-450 Enzyme System</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015971">Gene Expression Regulation, Enzymologic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007545">Isoproterenol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">dmd.108.023077</ArticleId>
            <ArticleId IdType="doi">10.1124/dmd.108.023077</ArticleId>
            <ArticleId IdType="pubmed">18725507</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18304461</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0366-6999</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>121</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Feb</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chinese medical journal</Title>
                <ISOAbbreviation>Chin. Med. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men.</ArticleTitle>
            <Pagination>
                <MedlinePgn>305-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Variation in prostate cancer incidence between different racial groups has been well documented, for which genetic polymorphisms are hypothesized to be an explanation. We evaluated the association between polymorphisms in the cytochrome P-450 CYP1A1 (CYP1A1) and glutathione S-transferase M1 (GSTM1) genes and genetic susceptibility to prostate cancer in Chinese men.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Two hundred and eight prostate cancer patients and 230 age matched controls were enrolled in this study. All DNA samples from peripheral blood lymphocytes were genotyped for common genetic polymorphisms of the CYP1A1 and GSTM1 genes using the oligonucleotide microarray (DNA chip) technique and the polymorphism results confirmed by sequencing. The different polymorphisms in prostate cancer patients were also analyzed according to age at diagnosis, prostate specific antigen level, cancer stage and grade (Gleason score).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of the GSTM1 (0/0) genotype was significantly higher in prostate cancer patients (58.2%) than in controls (41.7%, P&lt;0.05). Further analysis demonstrated that the prostate cancer patients with a GSTM1 (0/0) genotype were younger than those with the GSTM1 (+/+) genotype (P=0.024). No significant differences in the frequency distributions of CYP1A1 polymorphisms were observed between prostate cancer patients and controls.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">GSTM1 (0/0) gene polymorphism may be linked to prostate cancer risk and early age of onset in Chinese.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Peking University School of Oncology, Beijing Cancer Hospital &amp; Institute, Beijing 100036, China. mingli98@hotmail.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guan</LastName>
                    <ForeName>Tong-yu</ForeName>
                    <Initials>TY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yao</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Na</LastName>
                    <ForeName>Yan-qun</ForeName>
                    <Initials>YQ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Chin Med J (Engl)</MedlineTA>
            <NlmUniqueID>7513795</NlmUniqueID>
            <ISSNLinking>0366-6999</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D019363">Cytochrome P-450 CYP1A1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance UI="D005982">Glutathione Transferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance UI="C117740">glutathione S-transferase M1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019363">Cytochrome P-450 CYP1A1</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005787">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005982">Glutathione Transferase</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011110">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18304461</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18583979</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>06</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>07</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>04</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>40</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.</ArticleTitle>
            <Pagination>
                <MedlinePgn>827-34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.171</ELocationID>
            <Abstract>
                <AbstractText>In an effort to pinpoint potential genetic risk factors for schizophrenia, research groups worldwide have published over 1,000 genetic association studies with largely inconsistent results. To facilitate the interpretation of these findings, we have created a regularly updated online database of all published genetic association studies for schizophrenia ('SzGene'). For all polymorphisms having genotype data available in at least four independent case-control samples, we systematically carried out random-effects meta-analyses using allelic contrasts. Across 118 meta-analyses, a total of 24 genetic variants in 16 different genes (APOE, COMT, DAO, DRD1, DRD2, DRD4, DTNBP1, GABRB2, GRIN2B, HP, IL1B, MTHFR, PLXNA2, SLC6A4, TP53 and TPH1) showed nominally significant effects with average summary odds ratios of approximately 1.23. Seven of these variants had not been previously meta-analyzed. According to recently proposed criteria for the assessment of cumulative evidence in genetic association studies, four of the significant results can be characterized as showing 'strong' epidemiological credibility. Our project represents the first comprehensive online resource for systematically synthesized and graded evidence of genetic association studies in schizophrenia. As such, it could serve as a model for field synopses of genetic associations in other common and genetically complex disorders.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Allen</LastName>
                    <ForeName>Nicole C</ForeName>
                    <Initials>NC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bagade</LastName>
                    <ForeName>Sachin</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McQueen</LastName>
                    <ForeName>Matthew B</ForeName>
                    <Initials>MB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ioannidis</LastName>
                    <ForeName>John P A</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kavvoura</LastName>
                    <ForeName>Fotini K</ForeName>
                    <Initials>FK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khoury</LastName>
                    <ForeName>Muin J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanzi</LastName>
                    <ForeName>Rudolph E</ForeName>
                    <Initials>RE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bertram</LastName>
                    <ForeName>Lars</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 HD060726</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D030541">Databases, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005787">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018740">Genetic Heterogeneity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D008040">Genetic Linkage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>28</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>28</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.171</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.171</ArticleId>
            <ArticleId IdType="pubmed">18583979</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19303104</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3792</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>181</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of urology</Title>
                <ISOAbbreviation>J. Urol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2339-48</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2009.01.015</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Cyclophosphamide (Sigma) is associated with urological complications, including irritative voiding symptoms and hemorrhagic cystitis. Evidence suggests that tumor necrosis factor-alpha (R&amp;D Systems), interleukin-1beta and cyclooxygenase-2 are directly involved in the pathogenesis of cyclophosphamide induced cystitis and these molecules depend on transcription factor NF-kappaB for maximal secretion. Additionally, sesquiterpene lactone parthenolide has been shown to be a potent nuclear factor-kappaB inhibitor. We hypothesized that enhanced nuclear factor-kappaB activity contributes to cyclophosphamide induced cystitis and, therefore, it may be an attractive target for preventing cyclophosphamide cystitis. We determined whether parthenolide could be used as a preventive agent for hemorrhagic cystitis and bladder overactivity. Moreover, we determined the molecular mechanisms of parthenolide on the inhibitory action of nuclear factor-kappaB in inflammatory human benign urothelial cells.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Rats were pretreated with parthenolide or vehicle solution and administered cyclophosphamide. Histological analysis and cystometry were performed 24 hours after cyclophosphamide administration. Human urothelial cells were pretreated with parthenolide and stimulated with tumor necrosis factor-alpha. Western blotting and immunofluorescence were performed to determine activation of the cyclooxygenase-2 and nuclear factor-kappaB pathway.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Parthenolide pretreatment inhibited bladder inflammation as well as bladder overactivity and it was also associated with nuclear factor-kappaB activation in the bladder. Parthenolide dose dependently suppressed tumor necrosis factor-alpha induced cyclooxygenase-2 expression and prevented nuclear factor-kappaB phosphorylation as well as nuclear factor-kappaB nuclear translocation and IkappaBalpha phosphorylation/degradation.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Nuclear factor-kappaB may have a crucial role in the pathogenesis of cyclophosphamide induced cystitis models. Parthenolide ameliorates bladder inflammation and bladder overactivity, and it might be a promising agent for preventing cyclophosphamide induced complications.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kiuchi</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takao</LastName>
                    <ForeName>Tetsuya</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamamoto</LastName>
                    <ForeName>Keisuke</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakayama</LastName>
                    <ForeName>Jiro</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miyagawa</LastName>
                    <ForeName>Yasushi</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsujimura</LastName>
                    <ForeName>Akira</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nonomura</LastName>
                    <ForeName>Norio</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okuyama</LastName>
                    <ForeName>Akihiko</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>03</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Urol</MedlineTA>
            <NlmUniqueID>0376374</NlmUniqueID>
            <ISSNLinking>0022-5347</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2RDB26I5ZB</RegistryNumber>
                <NameOfSubstance UI="C002669">parthenolide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Urol. 2009 May;181(5):1987-8</RefSource>
                <PMID Version="1">19286223</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001707">Biopsy, Needle</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003556">Cystitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011336">Probability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011897">Random Allocation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012717">Sesquiterpenes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053201">Urinary Bladder, Overactive</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0022-5347(09)00037-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.juro.2009.01.015</ArticleId>
            <ArticleId IdType="pubmed">19303104</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2346952</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>07</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>07</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0008-6363</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>24</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cardiovascular research</Title>
                <ISOAbbreviation>Cardiovasc. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of haemorrhage induced hypotension on coronary blood flow in an anaesthetised two vessel canine coronary stenosis-occlusion model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>176-81</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="STUDY OBJECTIVE" NlmCategory="OBJECTIVE">Previous experiments from our group have shown that left anterior descending coronary occlusion in the presence of hypotension caused by intravenous glyceryl trinitrate in an open chest canine model caused endocardial flow to fall in myocardium supplied by a stenosed circumflex coronary artery. The aim of the present study was to assess the effects of hypotension in a similar open chest model but without the vasodilating effect of glyceryl trinitrate on coronary vessels.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Blood flow to and function of remote myocardium supplied by a stenosed circumflex coronary artery [gradient 27(SEM 3) mm Hg] was determined in anaesthetised dogs after haemorrhage induced hypotension [mean aortic pressure 70(3) mm Hg] and after left anterior descending coronary occlusion. Transmural blood flow was measured using microspheres and myocardial wall thickness with sonomicrometer crystals.</AbstractText>
                <AbstractText Label="SUBJECTS" NlmCategory="METHODS">11 healthy mongrel dogs were used, weight 25 kg (range 19-33).</AbstractText>
                <AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Haemorrhage induced hypotension in the setting of a circumflex stenosis reduced endocardial blood flow to the posterior myocardial bed from 0.84 (0.14) to 0.57(0.07) ml.min-1.g-1 but did not alter percent myocardial thickening. When the left anterior descending coronary artery was occluded in the presence of the circumflex stenosis and haemorrhage induced hypotension, there was no further decrease in endocardial blood flow to or thickening of the posterior myocardial bed, despite a reduction in mean coronary artery pressure from 54(3) to 43(3) mm Hg.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings are in contrast to our previous findings where hypotension was induced by glyceryl trinitrate. Remote myocardial ischaemia appears to be attenuated in this two vessel stenosis-occlusion model in which hypotension is produced by haemorrhage.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gascho</LastName>
                    <ForeName>J A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of Virginia School of Medicine, Charlottesville 22908.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawrence</LastName>
                    <ForeName>J H</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beller</LastName>
                    <ForeName>G A</ForeName>
                    <Initials>GA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>HL-26205</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL-28575</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Cardiovasc Res</MedlineTA>
            <NlmUniqueID>0077427</NlmUniqueID>
            <ISSNLinking>0008-6363</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003326">Coronary Circulation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003327">Coronary Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006439">Hemodynamics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006470">Hemorrhage</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007022">Hypotension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2346952</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">290280</PMID>
        <DateCreated>
            <Year>1979</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1979</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-953X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>136</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>1979</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of psychiatry</Title>
                <ISOAbbreviation>Am J Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Methylphenidate-induced Tourette syndrome: case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1334-5</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bremness</LastName>
                    <ForeName>A B</ForeName>
                    <Initials>AB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sverd</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Psychiatry</MedlineTA>
            <NlmUniqueID>0370512</NlmUniqueID>
            <ISSNLinking>0002-953X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>207ZZ9QZ49</RegistryNumber>
                <NameOfSubstance UI="D008774">Methylphenidate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006948">Hyperkinesis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008774">Methylphenidate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005879">Tourette Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1979</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1979</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1979</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">290280</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16892088</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>08</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>09</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0950-9232</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>25</Volume>
                    <Issue>34</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Aug</Month>
                        <Day>7</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncogene</Title>
                <ISOAbbreviation>Oncogene</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mitochondria in hematopoiesis and hematological diseases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4757-67</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Mitochondria are involved in hematopoietic cell homeostasis through multiple ways such as oxidative phosphorylation, various metabolic processes and the release of cytochrome c in the cytosol to trigger caspase activation and cell death. In erythroid cells, the mitochondrial steps in heme synthesis, iron (Fe) metabolism and Fe-sulfur (Fe-S) cluster biogenesis are of particular importance. Mutations in the specific delta-aminolevulinic acid synthase (ALAS) 2 isoform that catalyses the first and rate-limiting step in heme synthesis pathway in the mitochondrial matrix, lead to ineffective erythropoiesis that characterizes X-linked sideroblastic anemia (XLSA), the most common inherited sideroblastic anemia. Mutations in the adenosine triphosphate-binding cassette protein ABCB7, identified in XLSA with ataxia (XLSA-A), disrupt the maturation of cytosolic (Fe-S) clusters, leading to mitochondrial Fe accumulation. In addition, large deletions in mitochondrial DNA, whose integrity depends on a specific DNA polymerase, are the hallmark of Pearson's syndrome, a rare congenital disorder with sideroblastic anemia. In acquired myelodysplastic syndromes at early stage, exacerbation of physiological pathways involving caspases and the mitochondria in erythroid differentiation leads to abnormal activation of a mitochondria-mediated apoptotic cell death pathway. In contrast, oncogenesis-associated changes at the mitochondrial level can alter the apoptotic response of transformed hematopoietic cells to chemotherapeutic agents. Recent findings in mitochondria metabolism and functions open new perspectives in treating hematopoietic cell diseases, for example various compounds currently developed to trigger tumor cell death by directly targeting the mitochondria could prove efficient as either cytotoxic drugs or chemosensitizing agents in treating hematological malignancies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fontenay</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Inserm U567, Institut Cochin, Department of Hematology, Paris, Cedex, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cathelin</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amiot</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gyan</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Solary</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Oncogene</MedlineTA>
            <NlmUniqueID>8711562</NlmUniqueID>
            <ISSNLinking>0950-9232</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E1UOL152H7</RegistryNumber>
                <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016922">Cell Aging</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002454">Cell Differentiation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004272">DNA, Mitochondrial</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006402">Hematologic Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006410">Hematopoiesis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007501">Iron</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>171</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1209606</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.onc.1209606</ArticleId>
            <ArticleId IdType="pubmed">16892088</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2572264</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0306-5251</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>28 Suppl 1</Volume>
                    <PubDate>
                        <Year>1989</Year>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of clinical pharmacology</Title>
                <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Contrasting effects of single doses of pindolol and xamoterol on left ventricular diastolic function.</ArticleTitle>
            <Pagination>
                <MedlinePgn>84S-85S</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Impaired left ventricular diastolic dysfunction is common in patients with ischaemic heart failure. The beta 1-adrenoceptor partial agonist xamoterol was compared with pindolol, a beta-adrenoceptor blocker with intrinsic sympathomimetic activity, in a haemodynamic study in 17 patients with ischaemic heart disease. Pindolol caused left ventricular end-diastolic pressure, wall stress and T1 to rise, whereas xamoterol produced improvements in all three parameters. These results suggest that xamoterol may be of greater benefit to patients in heart failure.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rousseau</LastName>
                    <ForeName>M F</ForeName>
                    <Initials>MF</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Louvain, Brussels, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pouleur</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Debaisieux</LastName>
                    <ForeName>J C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Eyll</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Charlier</LastName>
                    <ForeName>A A</ForeName>
                    <Initials>AA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>7503323</NlmUniqueID>
            <ISSNLinking>0306-5251</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000318">Adrenergic beta-Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011412">Propanolamines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7HE0JQL703</RegistryNumber>
                <NameOfSubstance UI="D017307">Xamoterol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BJ4HF6IU1D</RegistryNumber>
                <NameOfSubstance UI="D010869">Pindolol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Cardiol. 1983 May 1;51(8):1267-74</RefSource>
                <PMID Version="1">6133444</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1982;13(Suppl 2):193S-198S</RefSource>
                <PMID Version="1">7104142</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000318">Adrenergic beta-Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003327">Coronary Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003971">Diastole</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006339">Heart Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010869">Pindolol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011412">Propanolamines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017307">Xamoterol</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1379885</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2572264</ArticleId>
            <ArticleId IdType="pmc">PMC1379885</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2189795</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>07</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>07</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0017-6001</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>30</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1990</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Gynäkologische Rundschau</Title>
                <ISOAbbreviation>Gynakol Rundsch</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Hydrops fetalis in tachycardia: diagnostic and therapeutic procedures].</ArticleTitle>
            <Pagination>
                <MedlinePgn>28-39</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We report on a 33-year-old para II who was admitted to our hospital in her 29th gestational week with extensive fetal hydrops. Examinations showed a fetal supraventricular tachycardia with biventrical cardiac insufficiency. Digoxin was given both to the mother and to the fetus. At first, this treatment seemed to have no effect. Over a period of several weeks, however, oral therapy with digoxin and verapamil resulted in a stabilized fetal heart rate (175-180 beats/min). Signs of fetal cardiac insufficiency disappeared almost completely. In the 39th week the child was born spontaneously. Clinical examination revealed only a slight cardiac insufficiency. New possibilities of intrauterine therapy are discussed in the light of this case and other reports in the literature.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Karrer</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Klinik und Poliklinik für Geburtshilfe, Departement für Frauenheilkunde, Universitätsspital, Zürich, Schweiz.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baumann</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vetter</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dudenhausen</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huch</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arbenz</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Hydrops fetalis bei Tachykardie: Diagnostisches und therapeutisches Vorgehen.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>SWITZERLAND</Country>
            <MedlineTA>Gynakol Rundsch</MedlineTA>
            <NlmUniqueID>0011363</NlmUniqueID>
            <ISSNLinking>0017-6001</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>73K4184T59</RegistryNumber>
                <NameOfSubstance UI="D004077">Digoxin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>CJ0O37KU29</RegistryNumber>
                <NameOfSubstance UI="D014700">Verapamil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004077">Digoxin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006333">Heart Failure</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006340">Heart Rate, Fetal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015160">Hydrops Fetalis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011263">Pregnancy Trimester, Third</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013617">Tachycardia, Supraventricular</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014700">Verapamil</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>59</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2189795</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10083207</PMID>
        <DateCreated>
            <Year>1999</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1999</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0041-1345</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>31</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <MedlineDate>1999 Feb-Mar</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Transplantation proceedings</Title>
                <ISOAbbreviation>Transplant. Proc.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha.</ArticleTitle>
            <Pagination>
                <MedlinePgn>494-5</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fischer</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University Hospital Eppendorf, Hamburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sterneck</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valentin-Gamazo</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feucht</LastName>
                    <ForeName>H H</ForeName>
                    <Initials>HH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malagó</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Broelsch</LastName>
                    <ForeName>C E</ForeName>
                    <Initials>CE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Transplant Proc</MedlineTA>
            <NlmUniqueID>0243532</NlmUniqueID>
            <ISSNLinking>0041-1345</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>49717AWG6K</RegistryNumber>
                <NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000740">Anemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001803">Blood Transfusion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004279">DNA, Viral</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006084">Graft Rejection</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006526">Hepatitis C</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008111">Liver Function Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D016031">Liver Transplantation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011183">Postoperative Complications</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012254">Ribavirin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>3</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10083207</ArticleId>
            <ArticleId IdType="pii">S0041-1345(98)01725-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6887302</PMID>
        <DateCreated>
            <Year>1983</Year>
            <Month>10</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1983</Year>
            <Month>10</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0731-3810</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>20</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1983</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of toxicology. Clinical toxicology</Title>
                <ISOAbbreviation>J. Toxicol. Clin. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cholestatic jaundice and hematuria due to hypersensitivity to cefaclor in a child.</ArticleTitle>
            <Pagination>
                <MedlinePgn>79-84</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bosio</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Toxicol Clin Toxicol</MedlineTA>
            <NlmUniqueID>8213460</NlmUniqueID>
            <ISSNLinking>0731-3810</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>69K7K19H4L</RegistryNumber>
                <NameOfSubstance UI="D002433">Cefaclor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>OBN7UDS42Y</RegistryNumber>
                <NameOfSubstance UI="D002506">Cephalexin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002433">Cefaclor</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002506">Cephalexin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002779">Cholestasis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004342">Drug Hypersensitivity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006417">Hematuria</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1983</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1983</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1983</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6887302</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7481858</PMID>
        <DateCreated>
            <Year>1995</Year>
            <Month>12</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1995</Year>
            <Month>12</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0093-7754</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>5 Suppl 12</Issue>
                    <PubDate>
                        <Year>1995</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Seminars in oncology</Title>
                <ISOAbbreviation>Semin. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions.</ArticleTitle>
            <Pagination>
                <MedlinePgn>26-32</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In a phase I study, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was given weekly by 3-hour infusion for 6 weeks concurrent with daily cranial irradiation as initial treatment for patients with newly diagnosed astrocytic brain tumors. The primary goal of the study was to establish the maximum tolerated dose of paclitaxel when administered by this schedule. Sixty patients were entered into the study and received at least one course of therapy. Fifty-six patients completed treatment. The treatment regimen was well tolerated, with minimal hematologic toxicity. Peripheral neuropathy was dose-limiting. Median survival was 9.2 months for patients with glioblastoma multiforme and has not been reached for patients with anaplastic astrocytoma or astrocytoma. The maximum tolerated dose of paclitaxel in this study was 250 mg/m2 administered weekly. However, because five of six patients receiving this dose of paclitaxel developed peripheral neuropathy, and because patients with brain tumors may adapt to a superimposed neuropathy less well than patients without pre-existing nervous system dysfunction, we propose 225 mg/m2 as the recommended dose for subsequent phase II trials.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Glantz</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brown University School of Medicine, Providence, RI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choy</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kearns</LastName>
                    <ForeName>C M</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akerley</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Egorin</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>CA-13943</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Semin Oncol</MedlineTA>
            <NlmUniqueID>0420432</NlmUniqueID>
            <ISSNLinking>0093-7754</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011838">Radiation-Sensitizing Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33069-62-4</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001254">Astrocytoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D016371">Cranial Irradiation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005909">Glioblastoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017567">Karnofsky Performance Status</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009422">Nervous System Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017239">Paclitaxel</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011292">Premedication</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011838">Radiation-Sensitizing Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012044">Regression Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1995</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1995</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1995</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7481858</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10470991</PMID>
        <DateCreated>
            <Year>1999</Year>
            <Month>10</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1999</Year>
            <Month>10</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0160-2446</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>34</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cardiovascular pharmacology</Title>
                <ISOAbbreviation>J. Cardiovasc. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Acute hypotensive, natriuretic, and hormonal effects of nifedipine in salt-sensitive and salt-resistant black normotensive and hypertensive subjects.</ArticleTitle>
            <Pagination>
                <MedlinePgn>346-53</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In a randomized double-blind study, we compared the short-term effects of nifedipine (10 mg 3x daily for 1 day) versus placebo on 24-h blood pressure, diuresis, natriuresis, urinary excretion of dopamine and metabolites, and on plasma renin activity (PRA) and plasma aldosterone levels in 18 black hypertensive (HT) patients [eight salt-resistant (HT-SR) and 10 salt-sensitive (HT-SS)], and in 20 black normotensive (NT) subjects (12 NT-SR and eight NT-SS) who were studied randomly with both a high- (HS) and a low-salt (LS) diet. In comparison to placebo, nifedipine significantly decreased 24-h mean BP in all groups either with HS or LS diets (all p&lt;0.05). With HS, greater hypotensive effects were achieved in NT-SS (-10+/-2 mm Hg) versus NT-SR (-3+/-1 mm Hg; p&lt;0.05) and in HT-SS (-18+/-2 mm Hg) versus HT-SR (-12+/-2 mm Hg; p&lt;0.05). In NT-SS and HT-SS, nifedipine induced greater (p&lt;0.05) BP decrease with HS (-10+/-2 and -18+/-2 mm Hg) than with LS (-4+/-1 and -9+/-1 mm Hg, respectively), whereas in NT-SR and HT-SR, the hypotensive effect did not differ between HS and LS. Nifedipine versus placebo significantly increased natriuresis and fractional excretion of sodium in all groups only with HS (p&lt;0.05) but not with LS diets. Only in HT-SS were the hypotensive and natriuretic effects of nifedipine significantly correlated (r = -0.77; p&lt;0.01). Nifedipine produced a similar increase of the urinary excretion of dopamine, L-DOPA, and of DOPAC in all subjects, which did not correlate with hypotensive and natriuretic effects. Nifedipine did not modify plasma levels of renin and of aldosterone except in NT-SS with HS, in whom nifedipine increased PRA levels (p &lt;0.05). We conclude that although nifedipine reduces BP in all groups of NT and HT with LS and HS diets, the effect is greater in salt-sensitive subjects with HS. Although in HT-SS with HS, the short-term natriuretic response to nifedipine may contribute to its hypotensive effects, the diuretic-natriuretic effect of nifedipine is not necessary for the expression of its hypotensive effect. Moreover, it is unlikely that any short-term effects of nifedipine either on the renal dopaminergic system or on the secretion of aldosterone explain nifedipine short-term hypotensive and diuretic-natriuretic effects.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Damasceno</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculdade Medicina Universidade Eduardo Mondlane, Maputo, Mozambique.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santos</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pestana</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serrão</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caupers</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soares-da-Silva</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Polónia</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Cardiovasc Pharmacol</MedlineTA>
            <NlmUniqueID>7902492</NlmUniqueID>
            <ISSNLinking>0160-2446</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004232">Diuretics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4964P6T9RB</RegistryNumber>
                <NameOfSubstance UI="D000450">Aldosterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7647-14-5</RegistryNumber>
                <NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.23.15</RegistryNumber>
                <NameOfSubstance UI="D012083">Renin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I9ZF7L6G2L</RegistryNumber>
                <NameOfSubstance UI="D009543">Nifedipine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044383">African Continental Ancestry Group</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000450">Aldosterone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000959">Antihypertensive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003710">Demography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004232">Diuretics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007677">Kidney Function Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009318">Natriuresis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009543">Nifedipine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012083">Renin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012965">Sodium Chloride</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>9</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10470991</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">941915</PMID>
        <DateCreated>
            <Year>1976</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1976</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-9289</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>33</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1976</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of hospital pharmacy</Title>
                <ISOAbbreviation>Am J Hosp Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phlebitis associated with the intravenous use of cephalothin and cephapirin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>642-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The frequency and severity of phlebitis associated with cephalothin and cephapirin was compared in a double-blind study in 82 surgical patients with 149 different infusion sites. After treatment with the coded drug products, the status of each patient's veins was evaluated daily by i.v. therapists. Cephapirin was associated with a slightly lower rate of phlebitis, but the difference was not significant. For both drugs, the duration of therapy did not appear to have an effect on the rate of phlebitis. Scalp vein needles were associated with a lower rate of phlebitis than plastic catheters, but the difference was not significant.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sorrentino</LastName>
                    <ForeName>A P</ForeName>
                    <Initials>AP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haughey</LastName>
                    <ForeName>E J</ForeName>
                    <Initials>EJ</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cronin</LastName>
                    <ForeName>D W</ForeName>
                    <Initials>DW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bohen</LastName>
                    <ForeName>L N</ForeName>
                    <Initials>LN</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Hosp Pharm</MedlineTA>
            <NlmUniqueID>0370474</NlmUniqueID>
            <ISSNLinking>0002-9289</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002511">Cephalosporins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>89B59H32VN</RegistryNumber>
                <NameOfSubstance UI="D002514">Cephapirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R72LW146E6</RegistryNumber>
                <NameOfSubstance UI="D002512">Cephalothin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002511">Cephalosporins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002512">Cephalothin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002514">Cephapirin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007275">Injections, Intravenous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010689">Phlebitis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1976</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1976</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1976</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">941915</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22079489</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>03</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>09</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6844</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>99</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Epilepsy research</Title>
                <ISOAbbreviation>Epilepsy Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Changes in the cannabinoid (CB1) receptor expression level and G-protein activation in kainic acid induced seizures.</ArticleTitle>
            <Pagination>
                <MedlinePgn>64-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eplepsyres.2011.10.020</ELocationID>
            <Abstract>
                <AbstractText>It has been known for centuries that exogenous cannabinoids, such as tetrahydrocannabinol have anticonvulsant activity. Recent studies have advanced our understanding of the endogenous cannabinoid system and renewed the interest in cannabinoids as a potential treatment for epilepsy. The endogenous cannabinoid system is rapidly activated after seizure activity but still little is known about the molecular mechanisms underlying the role of the cannabinoid system in epilepsy. In this study epileptiform activity was induced by kainic acid (KA) and effects of the CB1 receptor agonists N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA) on G-protein signaling using the agonist-stimulated [(35)S]GTPγS binding assay were evaluated. Control and KA treated rat hippocampus and cortex membranes were used. Our results showed that the ACEA displayed a high potency and efficacy in stimulating the G-proteins and when compared to the control animals, significant enhancements were observed in tissues from the KA treated animals. Potency and efficacy values were in particular increased in the hippocampus tissues. Furthermore, gene expression levels of the cannabinoid receptor 1 (CB1) receptor and cannabinoid receptor interacting protein 1 (CRIP1) were measured by RT-PCR, where both CB1 and CRIP1 expressions were found to be elevated in the KA treated animals.</AbstractText>
                <CopyrightInformation>Copyright Â© 2011 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bojnik</LastName>
                    <ForeName>Engin</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, Temesvari krt 62, 6726 Szeged, Hungary. enginoboyniko@gmail.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Turunç</LastName>
                    <ForeName>Ezgi</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Armağan</LastName>
                    <ForeName>Güliz</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanıt</LastName>
                    <ForeName>Lütfiye</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Benyhe</LastName>
                    <ForeName>Sándor</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yalçın</LastName>
                    <ForeName>Ayfer</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borsodi</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Epilepsy Res</MedlineTA>
            <NlmUniqueID>8703089</NlmUniqueID>
            <ISSNLinking>0920-1211</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001095">Arachidonic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002186">Cannabinoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C540799">Cnrip1 protein, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D043884">Receptor, Cannabinoid, CB1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C119325">arachidonyl-2-chloroethylamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="D019204">GTP-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SIV03811UC</RegistryNumber>
                <NameOfSubstance UI="D007608">Kainic Acid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001095">Arachidonic Acids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002186">Cannabinoids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019204">GTP-Binding Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D005786">Gene Expression Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007608">Kainic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043884">Receptor, Cannabinoid, CB1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0920-1211(11)00328-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2011.10.020</ArticleId>
            <ArticleId IdType="pubmed">22079489</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2322997</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0143-3334</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Carcinogenesis</Title>
                <ISOAbbreviation>Carcinogenesis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Correlation between medium-term liver bioassay system data and results of long-term testing in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>561-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The effects of hepatocarcinogens (ethionine, thioacetamide, phenobarbital), non-hepatocarcinogens [N-ethyl-N-(4-hydroxybutyl)nitrosamine (EHBN), N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)] and a hepatoinhibitor [(butylated hydroxyanisole (BHA)] were compared in medium- and long-term in vivo systems. In experiment I, 2 weeks after a single injection of diethylnitrosamine (DEN) groups of male F344 rats received chemical administration for 6 weeks, combined with partial hepatectomy at week 3 and were killed at the end of week 8. In experiment II, animals were treated in the same manner and then given basal diet and tap water (group 1) or chemical continuously (group 2) until the 2 year timepoint. Numbers and areas of glutathione S-transferase placental form (GST-P)-positive foci developing in the liver under medium-term bioassay conditions (experiment I) were found to closely correlate with eventual hepatocellular carcinoma incidences after continuation of test chemical administration (experiment II). Thus all of the hepatocarcinogens enhanced both the induction of GST-P-positive focal lesions and liver tumors. While non-hepatocarcinogens exerted no such effects, their influence being limited to inducing lesions in their own respective target organs such as urinary bladder cancers in the EHBN case and glandular stomach adenocarcinomas with MNNG, BHA demonstrated inhibition potential in both experiments. The observed correlation between long- and medium-term results strongly indicates the applicability of our medium-term bioassay system for detection of liver carcinogens.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ogiso</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Nagoya City University Medical School, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tatematsu</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamano</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasegawa</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ito</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Carcinogenesis</MedlineTA>
            <NlmUniqueID>8008055</NlmUniqueID>
            <ISSNLinking>0143-3334</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002273">Carcinogens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>075T165X8M</RegistryNumber>
                <NameOfSubstance UI="D013853">Thioacetamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>12H3O2UGSF</RegistryNumber>
                <NameOfSubstance UI="D008769">Methylnitronitrosoguanidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>25013-16-5</RegistryNumber>
                <NameOfSubstance UI="D002083">Butylated Hydroxyanisole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3817-11-6</RegistryNumber>
                <NameOfSubstance UI="D002085">Butylhydroxybutylnitrosamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3IQ78TTX1A</RegistryNumber>
                <NameOfSubstance UI="D004052">Diethylnitrosamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>54897-62-0</RegistryNumber>
                <NameOfSubstance UI="C010723">N-ethyl-N-(4-hydroxybutyl)nitrosamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance UI="D005982">Glutathione Transferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WX1BN24WZT</RegistryNumber>
                <NameOfSubstance UI="D005001">Ethionine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YQE403BP4D</RegistryNumber>
                <NameOfSubstance UI="D010634">Phenobarbital</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002083">Butylated Hydroxyanisole</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002085">Butylhydroxybutylnitrosamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D015197">Carcinogenicity Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D002273">Carcinogens</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004052">Diethylnitrosamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004790">Enzyme Induction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005001">Ethionine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005982">Glutathione Transferase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008114">Liver Neoplasms, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008769">Methylnitronitrosoguanidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010634">Phenobarbital</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011916">Rats, Inbred F344</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013853">Thioacetamide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2322997</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2322995</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0143-3334</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Carcinogenesis</Title>
                <ISOAbbreviation>Carcinogenesis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparison of initiation potential of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in an in vivo carcinogen bioassay system.</ArticleTitle>
            <Pagination>
                <MedlinePgn>549-52</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A new approach to low-dose assessment of carcinogenic potential was applied to food contaminant pyrolysis products. Single intragastric doses of the carcinogenic pyrolysates, 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) or 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline MeIQx), were given 12 h after two-thirds partial hepatectomy (PH) to F344 male rats. Two weeks thereafter the animals were placed on a basal diet containing 0.05% phenobarbital (PB) for 6 weeks combined with an i.p. administration of D-galactosamine (300 mg/kg) to facilitate growth of initiated cells. Both IQ and MeIQx clearly caused initiation of hepatocarcinogenesis as revealed by induction of preneoplastic placental-form glutathione-S-transferase-positive (GST-P+) hepatocyte foci composed of more than three cells (approximately 30 microns in diameter). A similar protocol without performance of PH before pyrolysate administration gave a positive result only for the IQ-treated group indicating that cell proliferation is essential during the low-dose, one-shot initiation step. IQ was found to be two to three times more potent in inducing GST-P+ foci using both protocols. The current approach could find application in practical carcinogenicity screening of chemicals, for which only small amounts are available.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tsuda</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Nagoya City University Medical School, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamaguchi</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ozaki</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ito</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Carcinogenesis</MedlineTA>
            <NlmUniqueID>8008055</NlmUniqueID>
            <ISSNLinking>0143-3334</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002273">Carcinogens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009153">Mutagens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7535-00-4</RegistryNumber>
                <NameOfSubstance UI="D005688">Galactosamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>76180-96-6</RegistryNumber>
                <NameOfSubstance UI="C029216">2-amino-3-methylimidazo(4,5-f)quinoline</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>77500-04-0</RegistryNumber>
                <NameOfSubstance UI="C036990">2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline</NameOfSubstance>
            </Chemical>
            <Chemical>
         